Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease

Scandinavian Journal of Gastroenterology

Volumn 41, Issue 6, 2006, Pages 720-725

  Kolho, Kaija Leena ^a,b   Raivio, Taneli ^a   Lindahl, Harry ^a   Savilahti, Erkki ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Crohn's disease; Fecal tests; Glucocorticoids; Ulcerative colitis

Indexed keywords

ACETYLSALICYLIC ACID; BUDESONIDE; CALPROTECTIN; GLUCOCORTICOID; MESALAZINE; PREDNISOLONE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHILDHOOD DISEASE; COLITIS; COLON CROHN DISEASE; COLONOSCOPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; DOSE TIME EFFECT RELATION; ENTERITIS; ENZYME IMMUNOASSAY; FECES ANALYSIS; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; STEROID THERAPY; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADOLESCENT; ADRENAL CORTEX HORMONES; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; COLONOSCOPY; FECES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; SENSITIVITY AND SPECIFICITY;

EID: 33745714449     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520500419623     Document Type: Article

References (21)

1. Mamula P, Markowitz JE, Baldassano RN. Inflammatory bowel disease in early childhood and adolescence: special considerations. Gastroenterol Clin N Am 2003;32:967-95.
2. Kim SC, Ferry GD. Inflammatory bowel diseases in pediatric and adolescent patients: clinical, therapeutic, and psychosocial considerations. Gastroenterology 2004;126:1550-60.
3. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004;10:661-5.
4. Tibble JA, Bjarnason I. Non-invasive investigation of inflammatory bowel disease. World J Gastroenterol 2001;7:460-5.
5. Striz I, Trebichavsky I. Calprotectin: a pleiotropic molecule in acute and chronic inflammation. Physiol Res 2004;53:245-53.
6. Frosch M, Strey A, Vogl T, Wulffraat NM, Kuis W, Sunderkotter C, et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 2000;43:628-37.
7. Bunn SK, Bisset WM, Main MJC, Gray ES, Olson S, Golden BE. Fecal calprotectin: validation as a non-invasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001;33:14-22.
8. Fagerhol MK. Calprotectin, a faecal marker of organic gastrointestinal abnormality. Lancet 2000;356:1783.
9. Bunn SK, Bisset WM, Main MJC, Golden BE. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001;32:171-7.
10. Hsu K, Passey RJ, Endoh Y, Rahimi F, Youssef P, Yen T, et al. Regulation of S100A8 by glucocorticoids. J Immunol 2005;174:2318-26.
11. Gebhardt C, Breitenbach U, Tuckermann JP, Dittrich BT, Richter KH, Angel P. Calgranulins S100A8 and S100A9 are negatively regulated by glucocorticoids in a c-Fos-dependent manner and overexpressed throughout skin carcinogenesis. Oncogene 2002;20:4266-76.
12. Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004;39:1017-20.
13. Hyams JS, Ferry GD, Mandel FS, Gryboski JD, Kibort PM, Kirschner BS, et al. Development and validation of a paediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991;12:439-47.
14. Lorentzon Fagerberg U, Lööf L, Myrdal U, Hansson L-O, Finkel Y. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr 2005;40:450-5.
15. Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000;47:506-13.
16. Tibble J, Sigthorsson G, Foster R, Sherwood R, Fagerhol M, Bjarnason I. Gut 2001;49:402-8.
17. Escher JC, Taminiau JAJM, Nieuwenhuis EES, Buller HA, Grand RJ. Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm Bowel Dis 2003;9:34-58.
18. Beattie RM, Nicholls SW, Domizio P, Williams CB, Walker-Smith JA. Endoscopic assessment of the colonic response to corticosteroids in children with ulcerative colitis. J Pediatr Gastroenterol Nutr 1996;22:373-9.
19. Arnott IDR, Watts D, Ghosh S. Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease. Aliment Pharmacol Ther 2002;16:857-67.
20. Göke MN, Schneider M, Beil W, Manns MB. Differential glucocorticoid effects on repair mechanisms and NF-?B activity in the intestinal epithelium. Regul Pept 2002;105:203-14.
21. Gremse DA, Crissinger KD. Ulcerative colitis in children: medical management. Paediatr Drugs 2002;4:807-15.